258 related articles for article (PubMed ID: 12166945)
1. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
Widler L; Jaeggi KA; Glatt M; Müller K; Bachmann R; Bisping M; Born AR; Cortesi R; Guiglia G; Jeker H; Klein R; Ramseier U; Schmid J; Schreiber G; Seltenmeyer Y; Green JR
J Med Chem; 2002 Aug; 45(17):3721-38. PubMed ID: 12166945
[TBL] [Abstract][Full Text] [Related]
2. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Major P
Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
[TBL] [Abstract][Full Text] [Related]
3. Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies.
Green JR
Semin Oncol; 2001 Apr; 28(2 Suppl 6):4-10. PubMed ID: 11346859
[TBL] [Abstract][Full Text] [Related]
4. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Coleman RE
Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates: from the laboratory to the clinic and back again.
Russell RG; Rogers MJ
Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
7. Advances in the biology and treatment of myeloma bone disease.
Berenson JR
Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S16-20. PubMed ID: 11757204
[TBL] [Abstract][Full Text] [Related]
8. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Fitton A; McTavish D
Drugs; 1991 Feb; 41(2):289-318. PubMed ID: 1709854
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound.
Green JR; Müller K; Jaeggi KA
J Bone Miner Res; 1994 May; 9(5):745-51. PubMed ID: 8053405
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
11. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Vorotnjak M; Boos J; Lanvers-Kaminsky C
Anticancer Drugs; 2004 Sep; 15(8):795-802. PubMed ID: 15494642
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.
Berenson JR
Semin Oncol; 2001 Apr; 28(2 Suppl 6):25-34. PubMed ID: 11346862
[TBL] [Abstract][Full Text] [Related]
13. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
Berenson JR; Vescio R; Henick K; Nishikubo C; Rettig M; Swift RA; Conde F; Von Teichert JM
Cancer; 2001 Jan; 91(1):144-54. PubMed ID: 11148571
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Berenson JR; Rosen LS; Howell A; Porter L; Coleman RE; Morley W; Dreicer R; Kuross SA; Lipton A; Seaman JJ
Cancer; 2001 Apr; 91(7):1191-200. PubMed ID: 11283917
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].
Sakurai T
Clin Calcium; 2007 Jan; 17(1):24-8. PubMed ID: 17211090
[TBL] [Abstract][Full Text] [Related]
16. Current and future directions in medical therapy: hypercalcemia.
Body JJ
Cancer; 2000 Jun; 88(12 Suppl):3054-8. PubMed ID: 10898351
[TBL] [Abstract][Full Text] [Related]
17. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
Azuma Y; Sato H; Oue Y; Okabe K; Ohta T; Tsuchimoto M; Kiyoki M
Bone; 1995 Feb; 16(2):235-45. PubMed ID: 7756053
[TBL] [Abstract][Full Text] [Related]
18. The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium.
Twiss IM; Pas O; Ramp-Koopmanschap W; Den Hartigh J; Vermeij P
J Bone Miner Res; 1999 May; 14(5):784-91. PubMed ID: 10320527
[TBL] [Abstract][Full Text] [Related]
19. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
Maxwell C; Swift R; Goode M; Doane L; Rogers M
Clin J Oncol Nurs; 2003; 7(4):403-8. PubMed ID: 12929273
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of Paget's disease of bone: importance of the zoledronic acid].
Griz L; Colares V; Bandeira F
Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):845-51. PubMed ID: 17160207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]